INT16165

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1991
Last Reported 2011
Negated 17
Speculated 1
Reported most in Body
Documents 114
Total Number 119
Disease Relevance 35.13
Pain Relevance 3.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (DMD) cytoskeleton (DMD) nucleus (DMD)
cytoplasm (DMD)
Anatomy Link Frequency
spine 19
hip 14
radius 4
neck 3
gonadal 2
DMD (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 19 99.52 Very High Very High Very High
headache 250 99.36 Very High Very High Very High
transdermal 79 98.10 Very High Very High Very High
corticosteroid 112 98.06 Very High Very High Very High
rheumatoid arthritis 494 96.22 Very High Very High Very High
antagonist 30 91.44 High High
isoflurane 1 89.12 High High
withdrawal 53 88.64 High High
Pain 187 85.36 High High
fibrosis 223 84.56 Quite High
Disease Link Frequency Relevance Heat
Disease 651 100.00 Very High Very High Very High
Cognitive Disorder 54 99.88 Very High Very High Very High
Osteoporosis 3519 99.54 Very High Very High Very High
Headache 249 99.36 Very High Very High Very High
Asthma 4 99.28 Very High Very High Very High
Hypercalcemia 954 98.92 Very High Very High Very High
Frailty 376 98.84 Very High Very High Very High
Duchenne Muscular Dystrophy 1 98.80 Very High Very High Very High
Metastasis 58 98.76 Very High Very High Very High
Endometriosis (extended) 437 98.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Though the detailed size and portion of the deleted gene are not ascertained, the deletion in this case may not severely affect the function of dystrophin, unlike cases of Duchenne or Becker muscular dystrophy.
Neg (not) Regulation (affect) of dystrophin associated with duchenne muscular dystrophy
1) Confidence 0.60 Published 1991 Journal Rinsho Shinkeigaku Section Abstract Doc Link 1802475 Disease Relevance 0.44 Pain Relevance 0
Three cats affected with dystrophin deficiency and hypertrophic muscular dystrophy developed peracute rhabdomyolysis with a fatal outcome.
Regulation (affected) of dystrophin associated with rhabdomyolysis and frailty
2) Confidence 0.44 Published 1998 Journal Vet. Pathol. Section Abstract Doc Link 9539365 Disease Relevance 0.53 Pain Relevance 0.12
On the other hand, the MP group did not show any remarkable changes of BMD until the endpoint, in comparison to the control group.
Neg (not) Regulation (changes) of BMD
3) Confidence 0.38 Published 2010 Journal Acta Orthopaedica Section Body Doc Link PMC2876847 Disease Relevance 0.24 Pain Relevance 0
WBV is a new approach that is currently being tested for its effect on BMD and bone strength [51, 55].
Regulation (effect) of BMD
4) Confidence 0.34 Published 2011 Journal Journal of Aging Research Section Body Doc Link PMC3022164 Disease Relevance 0 Pain Relevance 0
Any potential benefit of WBV strongly depends on compliance and vibration stimulus that can be varied in multiple ways (including type, magnitude, frequency, and duration), and different types of vibration loading are likely to result in different effects on BMD [58].
Regulation (effects) of BMD
5) Confidence 0.34 Published 2011 Journal Journal of Aging Research Section Body Doc Link PMC3022164 Disease Relevance 0.08 Pain Relevance 0
However, an earlier meta-analysis results showed that walking had a positive significant effect on spine but not on femoral BMD [44].
Regulation (effect) of BMD in spine
6) Confidence 0.34 Published 2011 Journal Journal of Aging Research Section Body Doc Link PMC3022164 Disease Relevance 0 Pain Relevance 0
Initial, phase I/II studies demonstrated safety and efficacy of lasofoxifene given over a 600-fold dose range (from 0.017 mg/day to 10 mg/day) after an overnight fast.51,52,68,69 The overall results from the dose selection analyses suggested that the lowest lasofoxifene dose necessary to achieve a fully efficacious response on BMD and low-density lipoprotein cholesterol (LDL-C) levels is 0.25 mg/day.69–71 All lasofoxifene treatment regimens were also associated with improvements in vaginal atrophy measures, namely maturation index and vaginal pH, compared with placebo.
Regulation (response) of BMD associated with frailty
7) Confidence 0.26 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2817938 Disease Relevance 0.46 Pain Relevance 0
In contrast, the BMD at the lumbar spine was unaltered in both groups.
Regulation (unaltered) of BMD in spine
8) Confidence 0.23 Published 2006 Journal BMC Musculoskelet Disord Section Abstract Doc Link PMC1693558 Disease Relevance 0.21 Pain Relevance 0
Several studies showed that the effect of exercise on lumbar BMD in postmenopausal women seems to be quite modest (exercise > 1% versus control < 1%)[29] or even non-existent[30], and the walking program of the current study did not induce any effect, which could be attributed, in part, to the better health status of the subjects of the current study (no case of osteopenia/osteoporosis).


Regulation (effect) of BMD associated with osteoporosis
9) Confidence 0.23 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693558 Disease Relevance 0.56 Pain Relevance 0
Although moderate-intensity aerobic exercise interventions usually documented positive, but not statistically significant, increases in bone mass[28]; Verschueren et al. [15] reported positive effects on hip BMD but not in total body or lumbar spine BMD after 6 months of WBV using an up-and-down plate, lower amplitudes (1.7–2.5 mm) and higher frequencies (35–40 Hz) than the current study.
Regulation (effects) of BMD in spine
10) Confidence 0.23 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693558 Disease Relevance 0 Pain Relevance 0
In contrast, BMD at the lumbar spine was unaltered in both groups.
Regulation (unaltered) of BMD in spine
11) Confidence 0.23 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693558 Disease Relevance 0.08 Pain Relevance 0
The comparison of the changes in BMD at other sites on the hip showed a trend for the higher effectiveness of the vibratory exercise, but the difference did not reach statistical significance.
Regulation (changes) of BMD in hip
12) Confidence 0.23 Published 2006 Journal BMC Musculoskelet Disord Section Body Doc Link PMC1693558 Disease Relevance 0.14 Pain Relevance 0
While we cannot totally discount early hip joint degenerative change influencing hip BMD, DXA measurements are conventionally made away from the joint margin making this explanation seem implausible.
Regulation (influencing) of BMD in hip
13) Confidence 0.22 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002767 Disease Relevance 0.83 Pain Relevance 0.05
Analysis of the putative genetic effects on variation and covariation of LDD and BMD may shed light on the underlying mechanism.
Regulation (effects) of BMD associated with disease
14) Confidence 0.22 Published 2010 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC3002767 Disease Relevance 0.82 Pain Relevance 0.03
Results from an earlier meta-analysis showed that walking with other AEXs significantly affected the BMD at spine, but not hip [46].
Neg (not) Regulation (affected) of BMD in hip
15) Confidence 0.21 Published 2011 Journal Journal of Aging Research Section Body Doc Link PMC3022164 Disease Relevance 0 Pain Relevance 0
Hatori et al. [8] reported that 7 months of walking with an intensity above 110% of the heart rate at its anaerobic threshold attenuated bone loss in the spine of postmenopausal women, whereas walking at an intensity below 90% of the heart rate at its anaerobic threshold had no influence on BMD.
Neg (no) Regulation (influence) of BMD in spine
16) Confidence 0.21 Published 2011 Journal Journal of Aging Research Section Body Doc Link PMC3022164 Disease Relevance 0 Pain Relevance 0
Raloxifene, the selective estrogen receptor modulator (SERM) has a fundamentally different mode of action from the bisphosphonates and two recent studies have compared their effects on BMD and bone turnover (Luckey et al 2004; Sambrook et al 2004).
Regulation (effects) of BMD
17) Confidence 0.15 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.19 Pain Relevance 0
At ten years, the effects on BMD and bone turnover of 5 mg and 10 mg daily continuous treatment with alendronate were compared with 20 mg for 2 years and then 5mg daily for years 3–5 (discontinuation group).
Regulation (effects) of BMD
18) Confidence 0.15 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0.06 Pain Relevance 0
The increase in BMD was independent of baseline BMD.
Neg (independent) Regulation (independent) of BMD
19) Confidence 0.15 Published 2006 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1936260 Disease Relevance 0 Pain Relevance 0
Patients pretreated with alendronate, however, showed no change in BMD after 6 months, and then a gradual rise in BMD was observed.
Neg (no) Regulation (change) of BMD
20) Confidence 0.14 Published 2007 Journal Clinical Interventions in Aging Section Body Doc Link PMC2686338 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox